BR112015019264A8 - cápsulas para o tratamento de helicobacter pylori e seu uso". - Google Patents

cápsulas para o tratamento de helicobacter pylori e seu uso". Download PDF

Info

Publication number
BR112015019264A8
BR112015019264A8 BR112015019264A BR112015019264A BR112015019264A8 BR 112015019264 A8 BR112015019264 A8 BR 112015019264A8 BR 112015019264 A BR112015019264 A BR 112015019264A BR 112015019264 A BR112015019264 A BR 112015019264A BR 112015019264 A8 BR112015019264 A8 BR 112015019264A8
Authority
BR
Brazil
Prior art keywords
treatment
pylori
helicobacter pylori
capsules
infection
Prior art date
Application number
BR112015019264A
Other languages
English (en)
Other versions
BR112015019264B1 (pt
BR112015019264A2 (pt
Inventor
Raday Gilead
Goldberg Guy
Gosselin Patrick
Fathi Reza
Original Assignee
Redhill Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51297592&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015019264(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Redhill Biopharma Ltd filed Critical Redhill Biopharma Ltd
Publication of BR112015019264A2 publication Critical patent/BR112015019264A2/pt
Publication of BR112015019264A8 publication Critical patent/BR112015019264A8/pt
Publication of BR112015019264B1 publication Critical patent/BR112015019264B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

resumo patente de invenção: "composições farmacêuticas para o tratamento de helicobacter pylori". uma forma de dosagem sólida oral simples compreendendo uma primeira composição de dosagem de liberação imediata tendo pelo menos dois agentes antibióticos e uma segunda composição de dosagem de liberação retardada tendo um inibidor de bomba de prótons é aqui provida. a forma de dosagem sólida oral simples de acordo com alguns aspectos da invenção pode ser usada para o tratamento de distúrbios associados com infecção por h. pylori ou a prevenção de recorrência de distúrbios associados com infecção por h. pylori.
BR112015019264-5A 2013-02-13 2014-02-12 Cápsulas para o tratamento de helicobacter pylori e seu uso BR112015019264B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361764385P 2013-02-13 2013-02-13
US201361764401P 2013-02-13 2013-02-13
US61/764,385 2013-02-13
US61/764,401 2013-02-13
PCT/US2014/016071 WO2014127025A1 (en) 2013-02-13 2014-02-12 Pharmaceutical compositions for the treatment of helicobacter pylori

Publications (3)

Publication Number Publication Date
BR112015019264A2 BR112015019264A2 (pt) 2017-07-18
BR112015019264A8 true BR112015019264A8 (pt) 2019-11-12
BR112015019264B1 BR112015019264B1 (pt) 2021-08-24

Family

ID=51297592

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015019264-5A BR112015019264B1 (pt) 2013-02-13 2014-02-12 Cápsulas para o tratamento de helicobacter pylori e seu uso

Country Status (26)

Country Link
US (7) US9050263B2 (pt)
EP (1) EP2956149B1 (pt)
JP (1) JP6494529B2 (pt)
KR (1) KR102062357B1 (pt)
CN (2) CN109893516A (pt)
AU (1) AU2014216373B2 (pt)
BR (1) BR112015019264B1 (pt)
CA (1) CA2900763C (pt)
CL (1) CL2015002253A1 (pt)
CY (1) CY1122113T1 (pt)
DK (1) DK2956149T3 (pt)
ES (1) ES2744406T3 (pt)
HK (1) HK1217645A1 (pt)
HR (1) HRP20191559T1 (pt)
HU (1) HUE052411T2 (pt)
IL (1) IL240387B (pt)
MX (1) MX368536B (pt)
NZ (1) NZ711754A (pt)
PH (1) PH12015501783B1 (pt)
PL (1) PL2956149T3 (pt)
PT (1) PT2956149T (pt)
RU (1) RU2671400C2 (pt)
SG (1) SG11201506318QA (pt)
SI (1) SI2956149T1 (pt)
UA (1) UA120249C2 (pt)
WO (1) WO2014127025A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2956149T3 (da) 2013-02-13 2019-09-09 Redhill Biopharma Ltd Farmaceutiske sammensætninger til behandling af helicobacter pylori
KR101884230B1 (ko) * 2016-02-29 2018-08-01 주식회사 유영제약 에소메프라졸을 포함하는 제제
TW201829003A (zh) * 2017-01-18 2018-08-16 台灣基督長老教會馬偕醫療財團法人馬偕紀念醫院 胃腸道感染腔內治療系統
EP3551186A4 (en) * 2017-10-15 2020-08-19 The Center for Digestive Diseases COMPOSITIONS AND METHODS FOR THE TREATMENT, IMPROVEMENT AND PREVENTION OF H. PYLORI INFECTIONS
CN108497546B (zh) * 2018-03-22 2021-03-19 宝可科技（上海）有限公司 一种烟用添加剂及其制备方法和用途
CN110354125A (zh) * 2019-08-12 2019-10-22 珠海赛隆药业股份有限公司 一种治疗幽门螺杆菌感染的组合物及其制剂和用途
US11878011B2 (en) 2020-05-07 2024-01-23 Redhill Biopharma Ltd. Method for eradicating Helicobacter pylori infection in patients regardless of body mass index
WO2023204640A1 (ko) * 2022-04-22 2023-10-26 한국생명공학연구원 헬리코박터 파일로리에 의한 위 점막 손상 관련 질환의 예방 또는 치료용 약학적 조성물 및 헬리코박터 파일로리 감염의 예방 또는 치료용 유효성분의 스크리닝 플랫폼
CN117398360B (zh) * 2023-12-14 2024-03-15 山东齐都药业有限公司 治疗幽门螺杆菌的复方制剂胶囊及其制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3980637A (en) * 1975-03-17 1976-09-14 Bristol-Myers Company Production of amoxicillin
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
WO1998022117A1 (en) 1996-11-22 1998-05-28 The Procter & Gamble Company Compositions for the treatment of gastrointestinal disorders containing bismuth, and nsaid and one or more antimicrobials
SE9700885D0 (sv) 1997-03-12 1997-03-12 Astra Ab New pharmaceutical formulation
SE9704869D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
AUPP325398A0 (en) * 1998-04-30 1998-05-21 Borody, Thomas J. Improved method for eradicating h. pylori
US5927500A (en) * 1998-06-09 1999-07-27 Milliken & Company Pharmaceutical containment package
JP2000128779A (ja) * 1998-10-20 2000-05-09 Mitsui Chemicals Inc 薬物放出制御型製剤
US20040213847A1 (en) * 2003-04-23 2004-10-28 Matharu Amol Singh Delayed release pharmaceutical compositions containing proton pump inhibitors
WO2005048979A2 (en) * 2003-10-06 2005-06-02 Torrent Pharmaceuticals Limited Pharmaceutical composition having casing with multiple micro tablets
US7981908B2 (en) * 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
FR2891459B1 (fr) 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
EP1803450A1 (en) * 2006-01-03 2007-07-04 Ferrer Internacional, S.A. Pharmaceutical compositions for the eradication of helicobacter pylori
AU2008273699A1 (en) * 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions of rifaximin
JP5260905B2 (ja) 2007-07-12 2013-08-14 株式会社ジャパンディスプレイ 有機ｅｌ表示装置
US8133739B2 (en) 2007-07-20 2012-03-13 Kowa Co., Ltd. Reagent for measurement of concentration of lead, and method for measurement of concentration of lead
WO2009017716A2 (en) 2007-07-27 2009-02-05 Depomed, Inc. Pulsatile gastric retentive dosage forms
CN101584681A (zh) * 2008-05-23 2009-11-25 黑龙江福和华星制药集团股份有限公司 一种用于治疗幽门螺旋杆菌感染的片剂胶囊
CN101607086B (zh) * 2009-07-21 2011-11-02 山西安特生物制药股份有限公司 一种复方铋剂组合物及其制备方法
CN102091084B (zh) * 2010-12-09 2012-05-09 王勇 一种复方胶囊及其制备方法
DK2956149T3 (da) * 2013-02-13 2019-09-09 Redhill Biopharma Ltd Farmaceutiske sammensætninger til behandling af helicobacter pylori

Also Published As

Publication number Publication date
AU2014216373A1 (en) 2015-08-27
CN105163743A (zh) 2015-12-16
RU2671400C2 (ru) 2018-10-31
UA120249C2 (uk) 2019-11-11
CA2900763A1 (en) 2014-08-21
US9050263B2 (en) 2015-06-09
US20150044283A1 (en) 2015-02-12
WO2014127025A1 (en) 2014-08-21
SG11201506318QA (en) 2015-09-29
BR112015019264B1 (pt) 2021-08-24
CY1122113T1 (el) 2020-11-25
CL2015002253A1 (es) 2016-07-29
IL240387A0 (en) 2015-09-24
NZ711754A (en) 2020-05-29
HRP20191559T1 (hr) 2019-11-29
US20140227353A1 (en) 2014-08-14
KR20150118176A (ko) 2015-10-21
US20190336451A1 (en) 2019-11-07
SI2956149T1 (sl) 2019-11-29
US10238606B2 (en) 2019-03-26
EP2956149A1 (en) 2015-12-23
US20160235681A1 (en) 2016-08-18
CA2900763C (en) 2021-04-06
KR102062357B1 (ko) 2020-01-03
PT2956149T (pt) 2019-09-20
US11135172B2 (en) 2021-10-05
US11931463B2 (en) 2024-03-19
JP6494529B2 (ja) 2019-04-03
US20190175512A1 (en) 2019-06-13
PL2956149T3 (pl) 2020-03-31
CN109893516A (zh) 2019-06-18
DK2956149T3 (da) 2019-09-09
PH12015501783A1 (en) 2015-12-07
RU2015138708A (ru) 2017-03-17
US10898439B2 (en) 2021-01-26
US20220062188A1 (en) 2022-03-03
AU2014216373B2 (en) 2017-12-21
EP2956149A4 (en) 2016-10-12
HK1217645A1 (zh) 2017-01-20
IL240387B (en) 2020-02-27
MX368536B (es) 2019-10-07
PH12015501783B1 (en) 2015-12-07
US9603806B2 (en) 2017-03-28
BR112015019264A2 (pt) 2017-07-18
MX2015010490A (es) 2015-10-30
ES2744406T3 (es) 2020-02-25
US9498445B2 (en) 2016-11-22
EP2956149B1 (en) 2019-06-19
HUE052411T2 (hu) 2021-04-28
JP2016508516A (ja) 2016-03-22
US20170189341A1 (en) 2017-07-06

Similar Documents

Publication Publication Date Title
BR112015019264A8 (pt) cápsulas para o tratamento de helicobacter pylori e seu uso".
BR112017006957A2 (pt) formulações farmacêuticas para a liberação por via oral de fármacos do tipo de peptídeo ou proteína
DOP2017000137A (es) Benzamidas sustituidas con 1,3–tiazol–2–ilo.
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
CO2018011935A2 (es) Derivados aromáticos de sulfonamida
BR112018013227A2 (pt) ?composições farmacêuticas ou kit para o uso, métodos para tratar câncer em um mamífero e uso de uma composição?
BR112016001678A2 (pt) Composição, método de fabricação de um comprimido, comprimido, forma de dosagem unitária, artigo de fabricação, e, uso de uma composição, de um comprimido ou de uma forma de dosagem unitária
BR112018071155A2 (pt) formas de dosagem de antagonista opioide de liberação modificada
RU2017116740A (ru) Комбинации для лечения рассеянного склероза
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
EA201991387A1 (ru) ТРИЦИКЛИЧЕСКИЕ ЕНОНЫ - ПРОИЗВОДНЫЕ ПИРИМИДИНА ДЛЯ ИНГИБИРОВАНИЯ ROR-γ И ДРУГИХ ПРИМЕНЕНИЙ
MX2022001796A (es) Metodos y composiciones para inhibir los sintomas asociados con la veisalgia.
IL280083A (en) A pharmaceutical dosage form that can be administered orally and with a modified release
CL2017000884A1 (es) Composición farmacéutica para usarse en el tratamiento o la prevención de deficiencias de vitaminas y minerales en pacientes que han sido sometidos a cirugía de derivación gástrica
BR112018068784A2 (pt) método para o tratamento de leucemia
ECSP19027578A (es) Composición farmacéutica con antagonista del receptor de mineralocorticoides y su uso
EA202090666A1 (ru) Применение содержащей бензоат композиции для лечения глициновой энцефалопатии
BR112023025552A2 (pt) Composições estabilizadas de apilimod e usos das mesmas
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação
BR112019002213A2 (pt) composições e o uso das mesmas para tratar ou prevenir rosácea
BR112018011138A2 (pt) formulações para administração intravenosa
BR112016018009A8 (pt) composição de cinamaldeído e zinco e seu uso
CO2019013645A2 (es) Dropropizina en combinación con ambroxol en la forma farmacéutica de jarabe y tabletas
AR110598A1 (es) Profármacos de principios activos citotóxicos con grupos enzimáticamente escindibles
AR108792A1 (es) Composiciones que comprenden timolol

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/02/2014, OBSERVADAS AS CONDICOES LEGAIS.